Eupraxia Pharmaceuticals (EPRX) Projected to Announce Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will likely be releasing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.26) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. On average, analysts expect Eupraxia Pharmaceuticals to post ($0.85) EPS for the current fiscal year and ($0.99) EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 0.3%

EPRX opened at $6.85 on Tuesday. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $7.57 and its 200 day moving average price is $7.34. Eupraxia Pharmaceuticals has a fifty-two week low of $5.25 and a fifty-two week high of $9.32.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 1st. Finally, Wedbush started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eupraxia Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $17.80.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.